|
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes |
Sep 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
Jul 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
Dec 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
Apr 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
Apr 2019 |
Blood |
Aplastic Anemia |
|
Genetics of Progression From MDS to Secondary Leukemia |
Jul 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
